You just read:

New Interim Phase II Clinical Data from the OPAL Study Demonstrate Encouraging Single Agent Response Rates for Tosedostat in Elderly Patients with Relapsed Refractory AML

News provided by

Cell Therapeutics, Inc.

Jun 06, 2011, 01:00 ET